Rare Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Rare

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Protocol SWOG S2012
Cancer Type: RARE

RANDOMIZED PHASE II/III TRIAL OF FIRST LINE PLATINUM/ETOPOSIDE WITH OR WITHOUT
ATEZOLIZUMAB (NSC#783608) IN PATIENTS WITH POORLY DIFFERENTIATED
EXTRAPULMONARY SMALL CELL NEUROENDOCRINE CARCINOMAS (NEC)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Protocol NRG HN010
Cancer Type: RARE

A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAÏVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Protocol Alliance A092001
Cancer Type: RARE

PHASE 2 RANDOMIZED TRIAL OF NEOADJUVANT OR PALLIATIVE CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY FOR PERITONEAL MESOTHELIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.